InMode Ltd. (INMD) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

InMode Ltd. (INMD) Healthcare & Pipeline Overview

InMode Ltd. designs, develops, and markets minimally invasive aesthetic medical devices leveraging radiofrequency technologies. The company offers a range of products for aesthetic procedures and women's health, positioning itself in the competitive medical device market with a focus on innovation and global expansion.

What Is the Investment Thesis for INMD?

InMode Ltd. presents a compelling investment case based on its innovative radiofrequency technologies and strong market position in the aesthetic medical device industry. With a P/E ratio of 10.6 and a profit margin of 23.3%, InMode demonstrates solid profitability and financial health. Key growth catalysts include the expansion of its product line into new applications and geographic markets. The company's high gross margin of 77.8% indicates strong pricing power and efficient cost management. However, the company's high beta of 2.12 suggests higher volatility compared to the market. Investors should monitor the competitive landscape and regulatory environment as potential risks. The company's focus on minimally invasive and non-invasive procedures aligns with growing consumer demand for less invasive aesthetic treatments.

Based on FMP financials and quantitative analysis

INMD Key Highlights

Market Cap of $865M reflects InMode's current valuation in the aesthetic medical device market.

• P/E Ratio of 10.6 indicates the company's stock price relative to its earnings per share, suggesting a potentially undervalued investment.
• Profit Margin of 23.3% demonstrates strong profitability and efficient operations within the medical device sector.
• Gross Margin of 77.8% highlights InMode's ability to maintain high profitability on its products and services.
• Beta of 2.12 suggests higher volatility compared to the market, indicating a potentially riskier investment.

Who Are INMD's Competitors?

INMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INMD's Key Strengths?

Proprietary radiofrequency technology

• Strong gross margins
• Diverse product portfolio
• Global presence

What Are INMD's Weaknesses?

High beta indicating volatility

• Dependence on aesthetic market trends
• Limited dividend payout

What Could Drive INMD Stock Higher?

Potential FDA approval for new applications of InMode's RF technology.

• Expansion of InMode's sales and marketing efforts in emerging markets.
• Continued innovation and development of new products based on RF technology.

What Are the Key Risks for INMD?

Increased competition from established medical device companies and emerging startups.

• Stringent regulatory requirements and potential delays in product approvals.
• Economic downturns affecting consumer spending on aesthetic procedures.
• Dependence on the aesthetic market and changing consumer preferences.

What Are the Growth Opportunities for INMD?

• Expansion into Women's Health: InMode has the opportunity to further penetrate the women's health market with its innovative radiofrequency technologies. This includes addressing conditions such as stress urinary incontinence and vaginal laxity. The women's health market is a significant and growing segment within the medical device industry, offering substantial revenue potential for InMode. Successful expansion into this area could diversify InMode's revenue streams and enhance its market position.
• Geographic Expansion: InMode can drive growth by expanding its presence in emerging markets, particularly in Asia-Pacific and Latin America. These regions are experiencing increasing demand for aesthetic procedures due to rising disposable incomes and growing awareness of aesthetic treatments. Establishing strategic partnerships and distribution networks in these markets will be crucial for InMode to capitalize on this growth opportunity. This expansion could significantly increase InMode's global market share.
• New Product Development: InMode can sustain its growth momentum by continuously innovating and developing new products based on its proprietary radiofrequency technologies. This includes exploring new applications in areas such as dermatology, plastic surgery, and other medical specialties. Investing in research and development is essential for InMode to maintain its competitive edge and meet the evolving needs of its customers. New product launches can drive revenue growth and attract new customers.
• Strategic Acquisitions: InMode can accelerate its growth through strategic acquisitions of complementary companies or technologies. This includes acquiring companies with expertise in related areas such as laser technology or injectables. Strategic acquisitions can provide InMode with access to new markets, technologies, and customer bases. Careful due diligence and integration are essential for successful acquisitions.
• Increased Direct-to-Consumer Marketing: InMode can increase brand awareness and drive demand for its products by increasing its direct-to-consumer marketing efforts. This includes utilizing social media, online advertising, and other digital channels to reach potential customers. Educating consumers about the benefits of InMode's technologies and procedures can drive demand and increase sales. Effective marketing campaigns can enhance InMode's brand recognition and market share.

What Are INMD's Competitive Advantages?

• Proprietary radiofrequency assisted lipolysis (RFAL) technology.
• Strong brand reputation and customer loyalty.
• Extensive portfolio of minimally invasive and non-invasive products.
• Global distribution network and established presence in key markets.

What Does INMD Do?

InMode Ltd., originally incorporated as Invasix Ltd. in 2008 and rebranded in November 2017, is a global leader in the design, development, manufacture, and marketing of minimally invasive aesthetic medical products. Headquartered in Yokneam, Israel, InMode has established a strong presence in the United States and internationally. The company's core technology revolves around its proprietary radiofrequency assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency (SDFR) technologies. These technologies power a diverse portfolio of products used in a wide array of aesthetic procedures, including liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. In addition to its minimally invasive solutions, InMode also offers non-invasive medical aesthetic products. These products target procedures such as permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, and the treatment of superficial benign vascular and pigmented lesions. Furthermore, InMode provides hands-free medical aesthetic products designed for skin tightening, fat reduction, and muscle stimulation. InMode's commitment to innovation and its comprehensive product range have solidified its position as a key player in the rapidly evolving aesthetic medical device market.

What Products and Services Does INMD Offer?

• Designs minimally invasive aesthetic medical products.
• Develops radiofrequency assisted lipolysis (RFAL) technologies.
• Manufactures medical devices for skin tightening and body contouring.
• Markets products for liposuction and skin rejuvenation.
• Offers solutions for women's health conditions.
• Provides non-invasive treatments for hair and wrinkle reduction.
• Develops hands-free devices for fat reduction and muscle stimulation.

How Does INMD Make Money?

• Sells minimally invasive aesthetic medical devices to physicians and medical spas.
• Generates revenue through direct sales and distribution partnerships.
• Provides training and support to customers on the use of its devices.
• Focuses on recurring revenue through consumables and service contracts.

What Industry Does INMD Operate In?

The medical device industry, particularly the aesthetic segment, is experiencing robust growth driven by increasing consumer demand for minimally invasive and non-invasive procedures. InMode operates within this dynamic landscape, competing with established players and emerging startups. The market is characterized by technological innovation, stringent regulatory requirements, and evolving consumer preferences. InMode's focus on radiofrequency technologies positions it well to capitalize on the trend towards less invasive treatments. The company's global presence allows it to tap into diverse markets and adapt to regional preferences. The aesthetic medical device market is projected to continue its growth trajectory, fueled by an aging population and increasing disposable incomes.

Who Are INMD's Key Customers?

• Physicians specializing in dermatology and plastic surgery.
• Medical spas and aesthetic clinics.
• Hospitals and outpatient surgical centers.
• Women seeking aesthetic and women's health treatments.

Company Profile

InMode Ltd. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Yokne'am, IL. The company is led by CEO Moshe Mizrahy. INMD has traded publicly since 2019.

Return on equity for InMode Ltd. stands at 13.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.6%, showing how much profit it generates from its asset base. INMD trades at a trailing price-to-earnings ratio of 10.63, below the Healthcare sector average of ~23x. Its free cash flow yield is 10.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.4%, the inverse of the P/E and a quick read on earnings relative to price.

INMD Valuation & Market Position

With a $865M market cap, InMode Ltd. sits in the small-cap segment of the market. Relative to its peer group, INMD's quantitative score of 47/100 is below the peer average of 80/100.

Quarterly Financial Performance: InMode Ltd.

Revenue for InMode Ltd. came in at $95.6M during Q2 2026, a 16.5% improvement versus the preceding quarter. The company recorded net income of $17.1M, with diluted EPS of $0.29. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, INMD averaged $0.31 in diluted EPS.

InMode Ltd.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.54 places it in the safe zone, indicating low near-term bankruptcy risk.

InMode Ltd. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses.

Wall Street analysts project InMode Ltd. revenue of about $370.1M for fiscal 2026, with EPS near $1.31. The estimate reflects 4 contributing analysts.

INMD Financials

INMD Latest News

INMD Analyst Consensus

INMD MoonshotScore

Common Questions About INMD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources